A
Ajai Chari
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 320
Citations - 7537
Ajai Chari is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 32, co-authored 239 publications receiving 4735 citations. Previous affiliations of Ajai Chari include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial,Brendan M. Weiss,Saad Z. Usmani,Seema Singhal,Ajai Chari,Nizar J. Bahlis,Andrew Belch,Amrita Krishnan,Robert Vescio,Maria-Victoria Mateos,Amitabha Mazumder,Robert Z. Orlowski,Heather J. Sutherland,Joan Bladé,Emma C. Scott,Albert Oriol,Jesus G. Berdeja,Mecide Gharibo,Don A. Stevens,Richard Leblanc,Michael Sebag,Natalie S. Callander,Andrzej Jakubowiak,Darrell White,Javier de la Rubia,Paul G. Richardson,Steen Lisby,Huaibao Feng,Clarissa M. Uhlar,Imran Khan,Tahamtan Ahmadi,Peter M. Voorhees +31 more
TL;DR: Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in this population of patients.
Journal ArticleDOI
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial,Hans C. Lee,Ashraf Badros,Suzanne Trudel,Ajay K. Nooka,Ajai Chari,Al-Ola Abdallah,Natalie S. Callander,Nikoletta Lendvai,Douglas W. Sborov,Attaya Suvannasankha,Katja Weisel,Lionel Karlin,Edward N. Libby,Bertrand Arnulf,Thierry Facon,Cyrille Hulin,K. Martin Kortüm,Paula Rodriguez-Otero,Saad Z. Usmani,Parameswaran Hari,Rachid Baz,Hang Quach,Philippe Moreau,Peter M. Voorhees,Ira Gupta,Axel Hoos,Eric Zhi,January Baron,Trisha Piontek,Eric Lewis,Roxanne C. Jewell,Elisha J. Dettman,Rakesh Popat,Simona Degli Esposti,Joanna Opalinska,Paul G. Richardson,Adam D. Cohen +37 more
TL;DR: Single-agent belantamab mafodotin shows anti-myeloma activity with a manageable safety profile in patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma
Ajai Chari,Dan T Vogl,Maria Gavriatopoulou,Ajay K. Nooka,Andrew Yee,Carol Ann Huff,Philippe Moreau,David Dingli,Craig E. Cole,S. Lonial,Meletios A. Dimopoulos,A. Keith Stewart,Joshua Richter,Ravi Vij,Sascha Tuchman,Marc S Raab,Katja Weisel,Michel Delforge,Robert F Cornell,David Kaminetzky,James E. Hoffman,Luciano J. Costa,Terri L. Parker,Moshe Yair Levy,Martin Schreder,Nathalie Meuleman,Laurent Frenzel,Mohamad Mohty,Sylvain Choquet,Gary J. Schiller,Raymond L Comenzo,Monika Engelhardt,Thomas Illmer,Philip Vlummens,Chantal Doyen,Thierry Facon,Lionel Karlin,Aurore Perrot,Klaus Podar,Michael Kauffman,Sharon Shacham,Lingling Li,Shijie Tang,Carla Picklesimer,Jean-Richard Saint-Martin,Marsha Crochiere,Hua Chang,Samir Parekh,Yosef Landesman,Jatin Shah,Paul G. Richardson,Sundar Jagannath +51 more
TL;DR: Selinexor-dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies.
Journal ArticleDOI
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari,Attaya Suvannasankha,Joseph W. Fay,Bertrand Arnulf,Jonathan L. Kaufman,Jainulabdeen J. Ifthikharuddin,Brendan M. Weiss,Amrita Krishnan,Suzanne Lentzsch,Raymond L. Comenzo,Jianping Wang,Kerri Nottage,Christopher Chiu,Nushmia Z. Khokhar,Tahamtan Ahmadi,Sagar Lonial +15 more
TL;DR: Aside from increased neutropenia, the safety profile of daratumumab plus pom-dex was consistent with that of the individual therapies, and deep, durable responses were observed in heavily treated patients.
Journal ArticleDOI
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees,Jonathan L. Kaufman,Jacob P. Laubach,Douglas W. Sborov,Brandi Reeves,Cesar Rodriguez,Ajai Chari,Rebecca Silbermann,Luciano J. Costa,Larry D. Anderson,Nitya Nathwani,Nina Shah,Yvonne A. Efebera,Sarah A. Holstein,Caitlin Costello,Andrzej Jakubowiak,Tanya M. Wildes,Robert Z. Orlowski,Kenneth H. Shain,Andrew J. Cowan,Sean Murphy,Yana Lutska,Huiling Pei,Jon Ukropec,Jessica Vermeulen,Carla de Boer,Daniela Hoehn,Thomas S. Lin,Paul G. Richardson +28 more
TL;DR: Daratumumab with RVd induction and consolidation improved depth of response in patients with transplant-eligible NDMM, with no new safety concerns.